Other Species / Isoforms
  EVL (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y16-p
ARASVMVyDDTsKKW
0 84
EVL (human) ARASVMVyDDTsKKW Y16-p
EVL (mouse) ARASVMVyDDTSKKW Y16-p
EVL (rat) ARASVMVYDDTSKKW Y16
S20-p
VMVyDDTsKKWVPIk
0 1
EVL (human) VMVyDDTsKKWVPIk S20-p
EVL (mouse) VMVyDDTSKKWVPIK S20
EVL (rat) VMVYDDTSKKWVPIK S20
K27-ub
sKKWVPIkPGQQGFS
0 2
EVL (human) sKKWVPIkPGQQGFS K27-ub
EVL (mouse) SKKWVPIKPGQQGFS K27
EVL (rat) SKKWVPIKPGQQGFS K27
Y39-p
GFSRINIyHNTASNT
0 10
EVL (human) GFSRINIyHNTASNT Y39-p
EVL (mouse) GFSRINIyHNTASST Y39-p
EVL (rat) GFSRINIYHNTASNT Y39
S130-p
RQVQNGPsPDEMDIQ
0 5
EVL (human) RQVQNGPsPDEMDIQ S130-p
EVL (mouse) RQVQNGPSPEEMDIQ S130
EVL (rat) RQVQNGPsPEEMDIQ S130-p
S152-p
HQQQRQEsLERRTsA
Upstream
0 4
Treatment
  • ischemia
EVL (human) HQQQRQEsLERRTsA S152-p
EVL (mouse) EQQHRQEsLERRISA S150-p
EVL (rat) EQQHRQEsLERRISA S150-p
S158-p
EsLERRTsATGPILP
Upstream
1 3
Kinase, in vitro:
  • PKACA (rat)
EVL (human) EsLERRTsATGPILP S158-p
EVL (mouse) EsLERRISATGPILP S156
EVL (rat) EsLERRISATGPILP S156
S171-p
LPPGHPSsAASAPVS
0 1
EVL (human) LPPGHPSsAASAPVS S171-p
EVL (mouse) LPPGHPSSAASTTLS S169
EVL (rat) LPPGHPSSAASATFS S169
S242-p
VQRPEDAsGGSsPSG
0 3
EVL (human) VQRPEDAsGGSsPSG S242-p
EVL (mouse) VQRPEDAsGGssPsG S240-p
EVL (rat) VQRPEDASGGSSPSG S240
S245
PEDAsGGSsPSGtSK
0 2
EVL (human) PEDAsGGSsPSGtSK S245
EVL (mouse) PEDAsGGssPsGTSK S243-p
EVL (rat) PEDASGGSSPSGTSK S243
S246-p
EDAsGGSsPSGtSKs
0 14
EVL (human) EDAsGGSsPSGtSKs S246-p
EVL (mouse) EDAsGGssPsGTSKS S244-p
EVL (rat) EDASGGSSPSGTSKS S244
S248
AsGGSsPSGtSKsDA
0 1
EVL (human) AsGGSsPSGtSKsDA S248
EVL (mouse) AsGGssPsGTSKSDA S246-p
EVL (rat) ASGGSSPSGTSKSDA S246
T250-p
GGSsPSGtSKsDANR
0 1
EVL (human) GGSsPSGtSKsDANR T250-p
EVL (mouse) GGssPsGTSKSDANR T248
EVL (rat) GGSSPSGTSKSDANR T248
S253-p
sPSGtSKsDANRAss
0 1
EVL (human) sPSGtSKsDANRAss S253-p
EVL (mouse) sPsGTSKSDANRAss S251
EVL (rat) SPSGTSKSDANRAsS S251
S259-p
KsDANRAssGGGGGG
Upstream
0 10
Treatment
  • ischemia
EVL (human) KsDANRAssGGGGGG S259-p
EVL (mouse) KSDANRAssGGGGGG S257-p
EVL (rat) KSDANRAsSGGGGGG S257-p
S260-p
sDANRAssGGGGGGL
0 4
EVL (human) sDANRAssGGGGGGL S260-p
EVL (mouse) SDANRAssGGGGGGL S258-p
EVL (rat) SDANRAsSGGGGGGL S258
S283-p
AKRRKAAsQSDKPAE
0 4
EVL (human) AKRRKAAsQSDKPAE S283-p
EVL (mouse) AKRRKAAsQTDKPAD S281-p
EVL (rat) AKRRKAASQTDKPAD S281
S296-p
AEKKEDEsQMEDPSt
0 1
EVL (human) AEKKEDEsQMEDPSt S296-p
EVL (mouse) ADRKEDESQTEDPsT S294
EVL (rat) ADRKEDENQTEDPST N294
S302
EsQMEDPStsPsPGT
0 1
EVL (human) EsQMEDPStsPsPGT S302
EVL (mouse) ESQTEDPsTsPsPGt S300-p
EVL (rat) ENQTEDPSTsPSPGS S300
T303-p
sQMEDPStsPsPGTR
0 1
EVL (human) sQMEDPStsPsPGTR T303-p
EVL (mouse) SQTEDPsTsPsPGtR T301
EVL (rat) NQTEDPSTsPSPGSR T301
S304-p
QMEDPStsPsPGTRA
0 38
EVL (human) QMEDPStsPsPGTRA S304-p
EVL (mouse) QTEDPsTsPsPGtRA S302-p
EVL (rat) QTEDPSTsPSPGSRA S302-p
S306-p
EDPStsPsPGTRAAs
0 8
EVL (human) EDPStsPsPGTRAAs S306-p
EVL (mouse) EDPsTsPsPGtRATS S304-p
EVL (rat) EDPSTsPSPGSRATS S304
T309
StsPsPGTRAAsQPP
0 1
EVL (human) StsPsPGTRAAsQPP T309
EVL (mouse) sTsPsPGtRATSQPP T307-p
EVL (rat) STsPSPGSRATSQPP S307
S313-p
sPGTRAAsQPPNSSE
0 2
EVL (human) sPGTRAAsQPPNSSE S313-p
EVL (mouse) sPGtRATSQPPNSSE S311
EVL (rat) SPGSRATSQPPNSSE S311
S329-p
GRKPWERsNsVEKPV
0 31
EVL (human) GRKPWERsNsVEKPV S329-p
EVL (mouse) GRKPWERsNsVEKPV S327-p
EVL (rat) GRKPWERsNsVEKPV S327-p
S331-p
KPWERsNsVEKPVss
Upstream
0 107
Treatment
  • angiotensin_2
  • anti-CD3
  • nocodazole
  • SII_angiotensin_2
EVL (human) KPWERsNsVEKPVss S331-p
EVL (mouse) KPWERsNsVEKPVSS S329-p
EVL (rat) KPWERsNsVEKPVSS S329-p
S337-p
NsVEKPVssILsRtP
0 6
EVL (human) NsVEKPVssILsRtP S337-p
EVL (mouse) NsVEKPVSSLLsRtP S335
EVL (rat) NsVEKPVSSLLSRVK S335
S338-p
sVEKPVssILsRtPs
0 7
EVL (human) sVEKPVssILsRtPs S338-p
EVL (mouse) sVEKPVSSLLsRtPs S336
EVL (rat) sVEKPVSSLLSRVKP S336
S341-p
KPVssILsRtPsVAK
0 21
EVL (human) KPVssILsRtPsVAK S341-p
EVL (mouse) KPVSSLLsRtPsVAK S339-p
EVL (rat) KPVSSLLSRVKPAGs S339
T343-p
VssILsRtPsVAKsP
0 18
EVL (human) VssILsRtPsVAKsP T343-p
EVL (mouse) VSSLLsRtPsVAKsP T341-p
EVL (rat) gap -
S345-p
sILsRtPsVAKsPEA
0 78
EVL (human) sILsRtPsVAKsPEA S345-p
EVL (mouse) SLLsRtPsVAKsPEA S343-p
EVL (rat) gap -
S349-p
RtPsVAKsPEAKsPL
Upstream
0 91
Treatment
  • angiotensin_2
  • ischemia
EVL (human) RtPsVAKsPEAKsPL S349-p
EVL (mouse) RtPsVAKsPEAKsPL S347-p
EVL (rat) gap -
S354-p
AKsPEAKsPLQsQPH
Upstream
0 37
Treatment
  • ischemia
  • nocodazole
EVL (human) AKsPEAKsPLQsQPH S354-p
EVL (mouse) AKsPEAKsPLQSQPH S352-p
EVL (rat) gap -
S358-p
EAKsPLQsQPHsRMk
0 6
EVL (human) EAKsPLQsQPHsRMk S358-p
EVL (mouse) EAKsPLQSQPHSRVK S356
EVL (rat) gap -
S362-p
PLQsQPHsRMkPAGs
0 2
EVL (human) PLQsQPHsRMkPAGs S362-p
EVL (mouse) PLQSQPHSRVKPAGs S360
EVL (rat) gap -
K365-ub
sQPHsRMkPAGsVND
0 1
EVL (human) sQPHsRMkPAGsVND K365-ub
EVL (mouse) SQPHSRVKPAGsVND K363
EVL (rat) SSLLSRVKPAGsVND K342
S369-p
sRMkPAGsVNDMALD
Upstream
0 31
Treatment
  • anti-CD3
  • ischemia
  • nocodazole
EVL (human) sRMkPAGsVNDMALD S369-p
EVL (mouse) SRVKPAGsVNDVGLD S367-p
EVL (rat) SRVKPAGsVNDVGLD S346-p
K399
VRELHKVKEEIIDAI
0 1
EVL (human) VRELHKVKEEIIDAI K399
EVL (mouse) VRELHKVKEEIIDAI K397
EVL (rat) VRELHKVkEEIIDAI K376-ac